CD8A and rheumatoid arthritis: Schwaneck et al. [10] reported that RA patients with mainly CD8+ and occasionally CD4+ T-LGLs mostly showed an indolent clinical course following rituximab (anti-CD20) and anti-IL6 receptor Ab treatment in addition to continuous MTX therapy and/or TNF inhibitors.